A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy
Condition(s) studied
Investigational drug(s) / intervention(s)
DJI136: DLL3 targeted CAR-T therapy administered by intravenous (i.v.) infusion.
Study summary
This is a Phase I/II, open-label, non-randomized, multi-center study in patients with extensive-stage small cell lung cancer (ES-SCLC) to determine the recommended dose(s) (RD) and to evaluate the safety, tolerability and preliminary efficacy of DJI136.
Eligibility
Primary outcome measure(s)
- All study parts: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) — Up to approximately 2 years
Number of participants with AEs and SAEs, including changes in vital signs, electrocardiograms (ECGs) and laboratory values qualifying and reported as AEs. - All study parts: Incidence and severity of dose-limiting toxicities (DLTs) — 28 days
Number of participants with DLTs. A DLT is defined as an adverse event or abnormal laboratory value of Common Terminology Criteria for Adverse Events (CTCAE) grade 3 or higher assessed as unrelated to disease, disease progression, intercurrent illness, or concomitant medications that occurs within the first 28 days after DJI136 infusion and meets the criteria defined in the protocol. Other clinically significant toxicities may be considered to be DLTs, even if not CTCAE grade 3 or higher. - Phase II Group A: Overall response rate (ORR) as per RECIST v1.1 — Up to approximately 2 years
Tumor response assessed by the investigator based on Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1). ORR per RECIST v1.1 is defined as the proportion of patients with a confirmed best overall response of Complete response (CR) or Partial response (PR).
Trial sites (7)
| Facility | City | Region | Status |
|---|---|---|---|
| University of Kentucky | Lexington | Kentucky | Recruiting |
| MD Anderson Cancer Center | Houston | Texas | Recruiting |
| Fred Hutchinson Cancer Center | Seattle | Washington | Recruiting |
| Novartis Investigative Site | Clayton | Victoria | Recruiting |
| Novartis Investigative Site | Singapore | Singapore | Recruiting |
| Novartis Investigative Site | Seoul | Seoul | Recruiting |
| Novartis Investigative Site | Seoul | South Korea | Recruiting |
More Novartis Pharmaceuticals trials in Australia
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07564401 on ClinicalTrials.gov ↗ ← All trials in Australia